Zhonglin Hao — University of Kentucky

800 Rose Street
40536 Lexington
United States

If you made any changes in Pure these will be visible here soon.

Education/Academic qualification

Post Doctoral Fellow, Emory University

2010

Residency, Mercer University

2007

Doctor of Philosophy, University Of Tokyo

1998

Master of Science, Tianjin University

1989

Doctor of Medicine, Inner Mongolia Normal University Huhho

1986

8 Active
9 Finished

Pdcd4-Rictor Interaction in Suppression of Lung Tumorigenesis
Yang, H., Chen, L., Fan, W., Hao, Z., Lee, E., Liu, X. & Zhan, C.
National Cancer Institute
9/20/23 → 8/31/28
Project: Research project
CCSG Pilot: Determining Mechanisms of Immunotherapy Resistance in KEAP1 and LKB1 Mutant Lung Cancers
Brainson, C., Durbin, E. B., Hao, Z., Jeong, J. C. & Liu, J.
National Cancer Institute
9/1/23 → 6/30/24
Project: Research project
23-LUN-132-RBI-PMC: Phase 1b Single Arm, Open-Label Trial of RYZ101 in Combination with Carboplatin + Etoposide + Atezolizumab in Subjects with Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Hao, Z.
RayzeBio Incorporated
7/18/23 → 7/18/25
Project: Research project
23-LUN-133-LB-PMC: LB2102-1001, A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Hao, Z.
Legend Biotech USA Incorporated
7/10/23 → 7/10/25
Project: Research project
22-LUN-129-NP-PMC: CAAA601A42101, A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Tislelizumab in Inducti
Hao, Z. & Chauhan, A.
Novartis (domestic)
8/23/22 → 6/12/24
Project: Research project